title: [Vildagliptin suppresses temporal lobe epilepsy by up-regulating glucagon-like peptide-1].
abstract: OBJECTIVE
  To investigate the effect of vildagliptin on pentamethazol (PTZ)-induced epilepsy in rats and explore the molecular mechanism.
  
  
  METHODS
  Samples of temporal cortex from 23 patients with temporal lobe epilepsy were collected as epilepsy group and samples of temporal cortex from 14 patients with brain trauma were used as control group. Ninety male SD rats were randomly divided into control group (group A), PTZ-induced epilepsy group (group B), saline 2 mL/kg group (group C), vildagliptin 2.5 mg/kg group (group D), vildagliptin 5mg/kg group (group D) and vildagliptin 10 mg/kg group (group F). Use chronic model of epilepsy induced by PTZ (35 mg/kg) intraperitoneal injection for 3 consecutive weeks, and changes of behavior were observed. The expression of GLP-1R was detected by Western blotting and immunohistochemical (IHC) staining, and the expression of GLP-1 was detected by enzyme-linked immunosorbent assay (ELISA). The location of GLP-1R was detected by immunofluorescent staining.
  
  
  RESULTS
  Immunofluorescent staining showed that the GLP-1R located in the neurons, and GLP-1R expression was obviously decreased both in patients with TLE and in rats with epilepsy. The latency time was prolonged and epilepsy attack time was decreased after vildagliptin treatment (P<0.05). GLP-1R expression was increased after vildagliptin treatment (P<0.05). ELISA showed the change of GLP-1 expression was the same as GLP-1R.
  
  
  CONCLUSIONS
  Vildagliptin can suppress temporal lobe epilepsy in rats by up-regulating GLP-1 and GLP-1R expressions.
authors.affiliation: Department of Neurosurgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.E-mail: 376311868@qq.com.
authors.forename: Yue-Tao
authors.initials: YT
authors.lastname: Wen
authors.forename: Kun-Lun
authors.initials: KL
authors.lastname: Wu
authors.forename: Quan-Hong
authors.initials: QH
authors.lastname: Shi
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D016022:Case-Control Studies; D004833:Epilepsy, Temporal Lobe / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013702:Temporal Lobe / Q000187:drug effects / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects*; D000077597:Vildagliptin / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000927:Anticonvulsants; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1; D000077597:Vildagliptin